October 25, 2026 · Science
Retatrutide cut the apnea-hypopnea index by 34.3 events an hour at the 9 mg dose in the trial of participants without diabetes, against 9.9 on placebo.
Data published in the New England Journal of Medicine showed that once-weekly subcutaneous injections decreased the apnea-hypopnea index (AHI) significantly more than placebo over 80 weeks. The trial cohorts enrolled participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight, with mean baseline values exceeding 55 events per hour. Media coverage has reported several different reduction numbers for the exact same dataset.
Three Reported AHI Figures from One Dataset
Retatrutide significantly lowered sleep apnea events compared to placebo, but news outlets have reported three different numbers for that change.
The trials evaluated weekly subcutaneous retatrutide, an investigational triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors. The clinical trial programme was funded by Eli Lilly. Investigators nested two specific studies within a broader research programme: TRIUMPH-1-OSA enrolled 243 adults without type 2 diabetes, while TRIUMPH-2-OSA enrolled 448 adults with type 2 diabetes. Both studies required a body-mass index of at least 27 and at least 15 breathing pauses per hour during sleep. Over roughly 80 weeks, participants underwent polysomnography at baseline, week 24, and week 80.
The three circulating reduction figures come from distinct analytical frameworks. The first number is an absolute change under a hybrid-treatment estimand. In TRIUMPH-1-OSA, participants receiving the 9 mg dose experienced an average reduction of 34.3 events per hour, compared to a drop of 9.9 events with placebo. The second number is the intention-to-treat (ITT) difference from placebo. For that same 9 mg cohort, the net difference attributable to the drug versus placebo was minus 24.7 events per hour. The third figure appeared in a report by the trade publication Sleep Review. That report noted a manufacturer statement that the 12 mg dose reduced AHI by up to 36.1 events per hour, or 60.6 percent from baseline. That trade report did not specify which statistical estimand generated the 36.1 figure.
All three numbers come from the same dataset and answer different questions. The published primary analysis used a hybrid estimand, which applied a hypothetical strategy to participants whose intercurrent events suggested treatment failure and a treatment-policy strategy elsewhere. The intention-to-treat figures are reported as differences from placebo. The 60.6 percent is a relative change from baseline rather than a comparison with the placebo arm.
| Reported Metric | Reported Value | Analytical Framework | What Each Figure Measures |
|---|---|---|---|
| Manufacturer Peak Figure | Up to 36.1 events/hr (60.6%) | Unspecified estimand | Relative reduction from baseline for the 12 mg group as cited by Sleep Review |
| Primary Hybrid Estimand | -34.3 events/hr (9 mg dose) | Hybrid-treatment strategy | Mean within-group change from baseline in TRIUMPH-1-OSA, handling treatment failures |
| Intention-to-Treat Difference | -24.7 events/hr (9 mg dose) | Treatment-policy strategy | Net difference between the 9 mg retatrutide arm and the placebo control arm |
Dose-by-Dose Results Across Both Phase 3 Trials
Retatrutide delivered substantial reductions in breathing pauses across both patient populations.
In TRIUMPH-1-OSA, participants were randomized equally across four groups: weekly subcutaneous doses of 4 mg, 9 mg, or 12 mg, or a matching placebo. The primary endpoint measured the change in AHI at 80 weeks for the 9 mg and 12 mg cohorts. Under the hybrid-treatment estimand, the 4 mg dose lowered AHI by 22.9 events per hour. The 9 mg dose produced a drop of 34.3 events per hour. The 12 mg dose lowered AHI by 31.7 events per hour. Placebo patients experienced a reduction of 9.9 events per hour.
Statistical differences versus placebo confirmed the treatment effect. In participants without diabetes, the net hybrid differences were minus 13.0 events per hour for 4 mg, minus 24.4 for 9 mg, and minus 21.9 for 12 mg. The ITT differences versus placebo were minus 13.2, minus 24.7, and minus 22.5 events per hour.
TRIUMPH-2-OSA examined adults living with type 2 diabetes. In this trial, mean baseline AHI stood at 55.9 events per hour. Under the hybrid estimand, AHI dropped by 19.2 events per hour on 4 mg, 24.7 events on 9 mg, and 25.4 events on 12 mg. Placebo patients saw a reduction of 10.3 events per hour. Net differences versus placebo under the ITT framework were minus 8.8 events per hour for 4 mg, minus 13.9 for 9 mg, and minus 15.0 for 12 mg. Across both studies, the authors concluded that retatrutide resulted in significantly greater decreases in AHI than placebo.
| Trial & Cohort | Retatrutide Dose | Mean AHI Change | Hybrid Difference vs Placebo (95% CI) | ITT Difference vs Placebo (95% CI) |
|---|---|---|---|---|
| TRIUMPH-1-OSA (No Diabetes) | 4 mg weekly | -22.9 events/hr | -13.0 (-23.0 to -3.0) | -13.2 (-22.6 to -3.9) |
| TRIUMPH-1-OSA (No Diabetes) | 9 mg weekly | -34.3 events/hr | -24.4 (-34.1 to -14.7) | -24.7 (-34.1 to -15.3) |
| TRIUMPH-1-OSA (No Diabetes) | 12 mg weekly | -31.7 events/hr | -21.9 (-32.2 to -11.5) | -22.5 (-31.9 to -13.1) |
| TRIUMPH-1-OSA (No Diabetes) | Placebo | -9.9 events/hr | Reference | Reference |
| TRIUMPH-2-OSA (With Diabetes) | 4 mg weekly | -19.2 events/hr | -8.9 (-15.9 to -2.0) | -8.8 (-15.8 to -1.7) |
| TRIUMPH-2-OSA (With Diabetes) | 9 mg weekly | -24.7 events/hr | -14.4 (-21.6 to -7.2) | -13.9 (-21.3 to -6.6) |
| TRIUMPH-2-OSA (With Diabetes) | 12 mg weekly | -25.4 events/hr | -15.1 (-22.5 to -7.7) | -15.0 (-22.5 to -7.4) |
| TRIUMPH-2-OSA (With Diabetes) | Placebo | -10.3 events/hr | Reference | Reference |
Trial Participant Demographics and Baseline Severity
The participants in these trials suffered from severe sleep apnea rather than borderline illness.
Sleep apnea severity is conventionally graded by AHI, and these cohorts sat at the severe end. Although the study eligibility criteria accepted individuals with an AHI of at least 15, the actual enrolled populations sat far higher. The mean baseline AHI was 58.6 events per hour in TRIUMPH-1-OSA and 55.9 events per hour in TRIUMPH-2-OSA. These values indicate that participants experienced nearly one airway obstruction or partial collapse every single minute of sleep.
Body weight was similarly elevated. Baseline mean body weight reached 119.6 kg in the group without diabetes and 115.9 kg in the group with diabetes. The trials registered on ClinicalTrials.gov under identifier NCT05929066 for TRIUMPH-1 and NCT05929079 for TRIUMPH-2. Sleep Review noted that the overall TRIUMPH clinical programme has enrolled more than 5,800 participants across four studies.
A patient whose test comes back near the 15-event threshold starts from a very different baseline than the average trial participant. While individuals with 58 events per hour achieved substantial numerical relief, their final AHI frequently remained within abnormal ranges.
Current FDA Approval Status for Sleep Apnea Medications
Retatrutide has no regulatory approval, and only one medication is approved by the FDA for obstructive sleep apnea today.
On December 20, 2024, the US Food and Drug Administration approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity. It was the first medication approved for the condition, and Eli Lilly makes it. Our detailed guide to GLP-1 benefits beyond weight loss outlines that approved indication and its clinical criteria.
Weight Loss Magnitude and Disease Remission Rates
Substantial weight reduction occurred alongside improvements in nighttime breathing, but disease remission was not universal.
In these two sleep apnea studies, weight loss served as a key secondary endpoint. Under the treatment-regimen estimand, mean body weight decreased by 12.5 percent to 22.2 percent across retatrutide doses in TRIUMPH-1-OSA, compared to a 4.8 percent loss with placebo. In TRIUMPH-2-OSA, weight reduction ranged from 12.1 percent to 18.5 percent with retatrutide, versus 5.6 percent with placebo.
MedicalXpress covered trial data for participants without diabetes on the 9 mg or 12 mg doses. Between 52 percent and 66 percent achieved at least a 50 percent reduction in breathing pauses. Furthermore, up to 52 percent of participants without diabetes and 40 percent of participants with diabetes achieved disease remission or reached mild disease. In the placebo arms, about 13 percent reached that status.
No figure in these trials tells an individual how much weight loss would clear their own apnea, because the trials measured group averages at fixed doses.
Safety Profile and Reported Adverse Events
Gastrointestinal symptoms represented the primary adverse events recorded during the 80-week trial period.
The publication in the New England Journal of Medicine, led by first author Ronald R. Grunstein, identified gastrointestinal disturbances as the most frequent side effects. Sleep Review reported that the observed adverse events aligned with the established safety profiles of incretin-based medications. The most commonly reported symptoms were nausea, diarrhoea, constipation, and vomiting.
The trial publications and press reports did not disclose numerical discontinuation rates or specific organ-system complication figures.
These trials do not establish long-term safety or cardiovascular outcomes.
Design Boundaries and Questions the Trials Leave Open
The TRIUMPH-OSA studies provide rigorous data, but several critical clinical questions remain unanswered.
First, the trials did not include an active comparator arm. Investigators did not test retatrutide head-to-head against positive airway pressure (PAP) therapy, the established standard of care for sleep apnea. Nor did they compare retatrutide directly against tirzepatide, the only approved medication for this condition. Our comparative analysis of retatrutide vs tirzepatide details the molecular and clinical differences between these two agents.
Second, the trials evaluated a specific patient profile. Every participant had obesity or overweight, with baseline body weight averaging over 115 kg. The findings do not apply to individuals with obstructive sleep apnea who have a normal body mass index.
Third, commercial factors remain entirely undefined. No price and no coverage information has been published for either drug. Retatrutide is investigational and has no approved product, and nothing in these trials speaks to whether or when that will change.
The Place of Diagnostic Testing
A diagnosis of sleep apnea starts with an objective measurement of breathing during sleep.
Readers can explore our guide to home sleep apnea tests to understand how respiratory events are measured outside a hospital laboratory. For individuals reviewing recent sleep study records, our breakdown of sleep apnea test results explains diagnostic thresholds, oxygen desaturation metrics, and severity scoring. Any therapeutic decision requires direct consultation with a qualified medical professional.
Sources
Primary scientific citations and regulatory announcements include the following documents (accessed October 2026):
- NEJM publication: Grunstein RR, et al. 'Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.' New England Journal of Medicine, published online October 21, 2026. DOI: 10.1056/NEJMoa2611477. PubMed ID: 42904878.
- FDA approval announcement: US Food and Drug Administration. 'FDA Approves First Medication for Obstructive Sleep Apnea.' Published December 20, 2024.
- TRIUMPH-1 trial registration: ClinicalTrials.gov. Identifier: NCT05929066 (TRIUMPH-1-OSA).
- TRIUMPH-2 trial registration: ClinicalTrials.gov. Identifier: NCT05929079 (TRIUMPH-2-OSA).
- Sleep Review report: Sleep Review Magazine. 'Lilly's Retatrutide Reduces OSA Severity in Phase 3 Trial.'
- MedicalXpress report: MedicalXpress. 'Triple-action weekly weight-loss drug reduces sleep apnea, trial shows.' Published October 2026.
Frequently Asked Questions
Does retatrutide help sleep apnea?
Retatrutide significantly reduced nighttime breathing interruptions in two phase 3 clinical trials published in the New England Journal of Medicine in October 2026. In the TRIUMPH-1-OSA trial, the 9 mg weekly dose lowered the apnea-hypopnea index by an average of 34.3 events per hour under a hybrid-treatment estimand, compared to 9.9 events with placebo. Between 52 percent and 66 percent of participants without diabetes on the higher doses achieved at least a 50 percent reduction in airway interruptions. However, retatrutide is investigational and has no approved product.
Is retatrutide approved for sleep apnea?
No, retatrutide is not approved for sleep apnea or any other medical condition. It is an investigational triple agonist being developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors. While the TRIUMPH-1 and TRIUMPH-2 phase 3 clinical trials evaluated its efficacy over 80 weeks, the drug has not been approved by the US Food and Drug Administration or any other health authority.
How does retatrutide work for sleep apnea?
Retatrutide acts as a single molecule that stimulates three distinct metabolic receptors: GIP, GLP-1, and glucagon. In the clinical trials, once-weekly injections produced substantial reductions in body weight, averaging between 12.1 percent and 22.2 percent across active dosing arms. In adults with obstructive sleep apnea, retatrutide produced weight loss and decreases in breathing pauses that exceeded placebo in both trials.
What weight loss drug is approved for sleep apnea?
Zepbound (tirzepatide) is the only medication approved by the US Food and Drug Administration for obstructive sleep apnea. The FDA granted approval on December 20, 2024, specifically for moderate to severe obstructive sleep apnea in adults with obesity. Zepbound is manufactured by Eli Lilly. The approved label requires that the medication be used in combination with a reduced-calorie diet and increased physical activity. No other weight loss compound holds an FDA indication for sleep apnea.
How much weight loss does it take to stop sleep apnea?
In the trials, participants lost 12 percent to 22 percent of body weight, while 39 percent to 52 percent on higher doses reached disease remission or mild status. However, clinical research cannot identify a universal percentage that eliminates sleep apnea for an individual patient.
Can retatrutide cause sleep apnea?
Clinical trial data indicate that retatrutide reduces rather than causes sleep apnea events. Across the TRIUMPH-1 and TRIUMPH-2 trials, patients receiving active drug experienced significant reductions in their apnea-hypopnea index compared to placebo. The most common adverse events reported were gastrointestinal symptoms, including nausea, diarrhoea, vomiting, and constipation. There is no evidence from the phase 3 trials suggesting that retatrutide initiates or worsens upper airway obstruction.
Are weight loss drugs covered by insurance for sleep apnea?
No price and no coverage information has been published for either drug. On December 20, 2024, the US Food and Drug Administration approved Zepbound (tirzepatide) as the first medication for obstructive sleep apnea. That approval is for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, and it is to be used in combination with a reduced-calorie diet and increased physical activity. The approved indication requires obesity. In contrast, retatrutide is an investigational molecule with no approved product. Because retatrutide is investigational, there is no coverage information or pricing available. Coverage questions belong with the reader's prescriber and insurer.
Does a weight loss drug replace a CPAP machine?
A weight loss medication does not automatically eliminate the need for positive airway pressure therapy. In the TRIUMPH trials, participants had severe baseline apnea averaging roughly 56 to 58 events per hour, and while AHI dropped significantly, many patients continued to experience abnormal breathing events. Any modification to continuous positive airway pressure (CPAP) usage must be supervised by a treating physician.